Clinical Trial

TT-702 in Patients With Advanced Solid Tumours.

Study acronym: CURATE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.
Protocol Amendment History 5 changes
critical Primary endpoint(s) modified 2026-08-13
notable Enrollment reduced: 188 -> 60 participants 2026-08-13
minor Trial arms changed: 6 -> 4 2026-08-13
notable Primary completion pushed: 2027-06 -> 2028-04 2026-08-13
minor Completion pushed: 2027-06 -> 2028-04 2026-08-13
Trial Details
NCT Number NCT05272709
Lead Sponsor Cancer Research UK
Collaborators: Teon Therapeutics, Inc.
Conditions Advanced Solid Tumors
Enrollment 60 participants
Start Date 2022-01-19
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-12